featured
Asciminib in CML After ABL Kinase Inhibitor Failure
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Asciminib in Chronic Myeloid Leukemia After ABL Kinase Inhibitor Failure
N. Engl. J. Med 2019 Dec 12;381(24)2315-2326, TP Hughes, MJ Mauro, JE Cortes, H Minami, D Rea, DJ DeAngelo, M Breccia, YT Goh, M Talpaz, A Hochhaus, P le Coutre, O Ottmann, MC Heinrich, JL Steegmann, MWN Deininger, JJWM Janssen, FX Mahon, Y Minami, D Yeung, DM Ross, MS Tallman, JH Park, BJ Druker, D Hynds, Y Duan, C Meille, F Hourcade-Potelleret, KG Vanasse, F Lang, DW KimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.